Characterization of the Platelet Inflammatory Response in NAFL and NASH
NCT05128253 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 44
Last updated 2022-01-13
Summary
The primary objective of the study is to identify which features of platelet activation promote the inflammatory response that underlies the progression from NAFL to NASH.
Therefore, the investigators plan:
1. To characterize and compare the platelet inflammatory phenotype in NAFL vs NASH patients
2. To study if and how the signaling pathways controlled by ITAM/ITIM-coupled receptors is dysregulated in NAFL vs NASH As a secondary objective the investigators will analyze platelet activation and inflammatory response in a subset of NAFL and NASH patients after 2, 4 and 6 hours from consumption of a high fat meal to test if and how the platelet inflammatory phenotype is promoted by post-prandial plasma lipids.
Conditions
- NASH - Nonalcoholic Steatohepatitis
- NAFLD
Interventions
- OTHER
-
High fat meal in a subset of patients with NAFL or NASH
In a subset of NAFL (n=11) and NASH (n=11) patients venous blood samples will also be taken 2 (T0+2h), 4 (T0+4h) and 6 (T0+6h) hours after consumption of a high fat meal.
Sponsors & Collaborators
-
University of Roma La Sapienza
collaborator OTHER -
Stefania Basili
lead OTHER
Principal Investigators
-
STEFANIA BASILI, MD · SAPIENZA UNIVERSITY- Department of Translational and Precision Medicine
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-12-06
- Primary Completion
- 2022-09-06
- Completion
- 2023-08-31
Countries
- Italy
Study Locations
More Related Trials
-
Liver Damage and Cardiometabolic Disorders in NAFLD
NCT04036357 ·Status: RECRUITING
-
Silymarin in NAFLD
NCT02973295 ·Status: WITHDRAWN ·Phase: PHASE4
-
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
NCT03912532 ·Status: COMPLETED ·Phase: PHASE2
-
Human Liver ORganoids as a Model to Study the Development of Non-Alcoholic SteatOhepatitis (NASH)
NCT06856252 ·Status: RECRUITING ·Phase: NA
-
Dapagliflozin Efficacy and Action in NASH
NCT03723252 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Imatinib in Advance Liver Fibrosis Patients
NCT05224128 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A One-Year, Randomized, Double-Blind, Placebo-Controlled Trial of Rosiglitazone in Non-Alcoholic Steatohepatitis
NCT00492700 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
NCT02927314 ·Status: COMPLETED ·Phase: PHASE2
-
Different Doses of ZED1227 vs. Placebo in NAFLD
NCT05305599 ·Status: COMPLETED ·Phase: PHASE2
-
NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)
NCT03968354 ·Status: UNKNOWN
-
A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD
NCT03950882 ·Status: COMPLETED ·Phase: PHASE1
-
A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
NCT03776175 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients
NCT02194894 ·Status: WITHDRAWN ·Phase: NA
-
A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar
NCT06193629 ·Status: RECRUITING ·Phase: NA
-
Integrated Approaches for Identifying Molecular Targets in Liver Disease
NCT03915002 ·Status: COMPLETED
-
Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism
NCT04395950 ·Status: WITHDRAWN ·Phase: PHASE1
-
Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis
NCT01950884 ·Status: UNKNOWN ·Phase: PHASE4
-
Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)
NCT05129904 ·Status: UNKNOWN
-
Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
NCT05357352 ·Status: COMPLETED
-
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
NCT02369536 ·Status: COMPLETED ·Phase: NA
-
Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
NCT04031729 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
NCT05966025 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Clinical Trial of Pentoxifylline in Patient With Cirrhosis
NCT00162552 ·Status: COMPLETED ·Phase: PHASE3
-
Follow-up of NAFLD Patients With MRI-PDFF
NCT04910178 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
NCT03350165 ·Status: COMPLETED ·Phase: PHASE2